Literature DB >> 1677898

Tryptase TL2 in the membrane of human T4+ lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp 120.

H Kido1, A Fukutomi, N Katunuma.   

Abstract

A novel membrane-bound serine esterase in cultured human T4+ lymphocytes, recently purified and named tryptase TL2, binds specifically to the external envelope protein gp 120 of HIV-1, interacting with its V3 domain. This binding was selectively blocked by inhibitors of tryptase TL2 with a GPCR sequence in their reactive site, synthetic peptides corresponding with the sequences of the V3 domains of various HIV-1 strains with the GPGR sequence, and antibody against tryptase TL2, or neutralizing antibody against the V3 domain of HTLV-IIIB. These findings suggest that tryptase TL2 is a binding protein of the V3 domain of HIV-1 envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677898     DOI: 10.1016/0014-5793(91)80981-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Evolutionary origin of a Kunitz-type trypsin inhibitor domain inserted in the amyloid beta precursor protein of Alzheimer's disease.

Authors:  K Ikeo; K Takahashi; T Gojobori
Journal:  J Mol Evol       Date:  1992-06       Impact factor: 2.395

Review 2.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

3.  Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody.

Authors:  S Lu; S D Putney; H L Robinson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4.

Authors:  A Werner; J A Levy
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.

Authors:  I T Harvima; R J Harvima; G Nilsson; L Ivanoff; L B Schwartz
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

8.  Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.

Authors:  N Yahi; J M Sabatier; S Baghdiguian; F Gonzalez-Scarano; J Fantini
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

9.  The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells.

Authors:  H Golding; J Manischewitz; L Vujcic; R Blumenthal; D S Dimitrov
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.